Asian Registry Study of Patients with Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis Conducted Across Multiple Asian Countries

What this Trial Is About

Researchers are conducting a multinational, multicenter observational study to collect detailed information on patients with myeloproliferative neoplasms MPN from Asia. This registry includes patients diagnosed between 2010 and 2025 and aims to gather data on clinical features, genetic characteristics, treatments, outcomes, and survival of these patients. The study involves centers in various Asian countries, including Hong Kong, Singapore, Malaysia, Taiwan, Korea, and Thailand. The study collects information both retrospectively and prospectively through routine clinic visits and medical record reviews. Data are gathered at diagnosis and approximately every six months thereafter, continuing until disease progression, death, or study conclusion. The main focus is on tracking disease progression to secondary myelofibrosis, progression-free survival, and overall survival over a ten-year period. Participants will be monitored through their regular medical appointments, with data collected on their disease status, treatment responses, and survival outcomes. Researchers will analyze this information to better understand MPN characteristics and outcomes among Asian patients. The observation period lasts up to ten years, providing long-term insights into the disease course and treatment effects.

Asian Myeloproliferative Neoplasm (MPN) Registry